* All development phases not applicable for 505(b)2 regulatory filings.
** Anticipated NDA submission based on current development timelines.
*** See warnings and full prescribing information. For more information, visit www.onsolis.com.
Marketed in the U.S. by Meda Pharmaceuticals.